Market Cap: $212.1M
Market Cap: $212.1M
Open
$1.36
Prev. Close
$0.8158
High
$1.38
Low
$1.33
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
Lineage Cell Therapeutics, Inc. trades on the New York Stock Exchange Arca under the ticker LCTX, priced in USD.
Lineage Cell Therapeutics, Inc. has a market capitalisation of $212.1M, based on its latest share price.
LCTX trades at 124.62 times its trailing 12-month earnings.
Over the past 52 weeks LCTX has traded between $0.7697 and $1.99.
No. Lineage Cell Therapeutics, Inc. does not currently pay a dividend.
Highly profitable: keeps 16.2% of revenue as net profit.
The analyst consensus rating for LCTX is Buy.
Brian Culley is the CEO of Lineage Cell Therapeutics, Inc., which is headquartered in Carlsbad.
Generated automatically from reported financial data. General information only, not financial advice.
### Lineage Cell Therapeutics: Pioneering Advancements in Cell Therapy Lineage Cell Therapeutics is at the forefront of the evolving landscape of regenerative medicine, particularly through its focus…
Lineage Cell Therapeutics Embraces New Frontiers in Cell Therapy Development Lineage Cell Therapeutics stands poised to make significant strides in the expansive field of regenerative medicine as the…
Cell Encapsulation Technology: A Game Changer for Diabetes Management Avant Technologies Inc. is at the forefront of innovation in the cell therapy manufacturing sector, particularly with its groundbr…
Lineage Cell Therapeutics Focuses on Advancing Cell Therapy Innovations Lineage Cell Therapeutics continues to push the boundaries of regenerative medicine as it advances its innovative cell therapies…